NBDHEX|cas:787634-60-0|西域试剂

NBDHEX,99.53%

产品编号：Bellancom-135318| CAS NO：787634-60-0| 分子式：C₁₂H₁₅N₃O₄S| 分子量：297.33

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-135318	￥900.00	杭州北京（现货）
Bellancom-135318	￥1500.00	杭州北京（现货）
Bellancom-135318	￥4500.00	杭州北京（现货）
Bellancom-135318	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NBDHEX

产品介绍

NBDHEX 是一种有效的谷胱甘肽 S-转移酶 P1-1 (GSTP1-1) 抑制剂。 NBDHEX 诱导肿瘤细胞凋亡。NBDHEX 通过抑制 GST 的催化活性，避免抑制剂被特异性泵从细胞中排出，以及破坏 GSTP1-1 和关键信号传导因子之间的相互作用，从而起到抗癌的作用。NBDHEX 也可以作为晚期自噬抑制剂。

生物活性

NBDHEX is a potent glutathione S-transferase P1-1 (GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor.

体外研究

NBDHEX (0.05-20 μM; 48 hours; H69 and H69AR cells) is cytotoxic toward cell lung cancer H69 and H69AR cells.
NBDHEX (0-5 μM; 24 hours; H69AR cells) treatment results in a dose-dependent apoptosis in the H69AR cell line.
NBDHEX (3 μM; 1-12 hours; H69AR cells) treatment increases the phosphorylation of JNK/c-Jun in H69AR cells in a time-dependent fashion.
NBDHEX treatment shows a marked increase in phosphorylation of p38^MAPK, and also increases GSSG content in a time-dependent manner in H69 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	H69 and H69AR cells
Concentration:	0.05-20 μM
Incubation Time:	48 hours
Result:	The dose-response profiles revealed a good cytotoxic activity both in sensitive H69 cell line (LC₅₀ of 2.3 μM) and in its Adriamycin-resistant counterpart H69AR (LC₅₀ of 4.5 μM).

Apoptosis Analysis

Cell Line:	H69AR cells
Concentration:	0 μM, 0.5 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM
Incubation Time:	24 hours
Result:	Resulted in a dose-dependent apoptosis in the H69AR cell line.

Western Blot Analysis

Cell Line:	H69AR cells
Concentration:	3 μM
Incubation Time:	1 hour,3 hours, 6 hours, 12 hours
Result:	Increased the phosphorylation of JNK/c-Jun in H69AR cells in a time-dependent fashion.

体内研究
(In Vivo)

NBDHEX (0.8-80 mg/kg/day; oral administration; daily; for 15 days; SCID female mice) treatment results a statistically significant tumour inhibition (approximately 70%).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID female mice (4-5 weeks) injected with Me501cells
Dosage:	0.8 mg/kg/day, 8.0 mg/kg/day or 80 mg/kg/day
Administration:	Oral administration; daily; for 15 days
Result:	A statistically significant tumour inhibition (approximately 70%) was observed.

体内研究

NBDHEX (0.8-80 mg/kg/day; oral administration; daily; for 15 days; SCID female mice) treatment results a statistically significant tumour inhibition (approximately 70%).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID female mice (4-5 weeks) injected with Me501cells
Dosage:	0.8 mg/kg/day, 8.0 mg/kg/day or 80 mg/kg/day
Administration:	Oral administration; daily; for 15 days
Result:	A statistically significant tumour inhibition (approximately 70%) was observed.

体内研究

NBDHEX (0.8-80 mg/kg/day; oral administration; daily; for 15 days; SCID female mice) treatment results a statistically significant tumour inhibition (approximately 70%).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID female mice (4-5 weeks) injected with Me501cells
Dosage:	0.8 mg/kg/day, 8.0 mg/kg/day or 80 mg/kg/day
Administration:	Oral administration; daily; for 15 days
Result:	A statistically significant tumour inhibition (approximately 70%) was observed.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (420.41 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3633 mL	16.8163 mL	33.6327 mL
5 mM	0.6727 mL	3.3633 mL	6.7265 mL
10 mM	0.3363 mL	1.6816 mL	3.3633 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.00 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.00 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.00 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.00 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明